Cargando…

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice

Long-term survival of high-risk neuroblastoma (NB) patients still remains under 50%. Here, we report the generation, in vitro characterization and anti-tumor effectivity of a new bicistronic xenogenic DNA vaccine encoding tyrosine hydroxylase (TH) that is highly expressed in NB tumors, and the immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marx, Madlen, Zumpe, Maxi, Troschke-Meurer, Sascha, Shah, Diana, Lode, Holger N., Siebert, Nikolai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242328/ https://www.ncbi.nlm.nih.gov/pubmed/30452438 http://dx.doi.org/10.1371/journal.pone.0207320

Ejemplares similares

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
por: Lode, Holger N., et al.
Publicado: (2023)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
por: Klingel, Leah, et al.
Publicado: (2022)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells
por: Forkel, Hannes, et al.
Publicado: (2022)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
por: Siebert, Nikolai, et al.
Publicado: (2018)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report
por: Lode, Holger N., et al.
Publicado: (2019)

Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma
por: Lee, Na Hee, et al.
Publicado: (2016)

Plasma dopamine-beta-hydroxylase in neuroblastoma.
por: Schöni, M., et al.
Publicado: (1984)

Serum dopamine beta hydroxylase in children with neuroblastoma.
por: Eldeeb, B. B., et al.
Publicado: (1983)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
por: Schriegel, Felix, et al.
Publicado: (2021)

Genetic diversity of tyrosine hydroxylase (TH) and dopamine β-hydroxylase (DBH) genes in cattle breeds
por: Lourenco-Jaramillo, Diana Lelidett, et al.
Publicado: (2012)

An unusual presentation of tyrosine hydroxylase deficiency
por: Katus, Linn E., et al.
Publicado: (2017)

Purkinje Cell-Specific Knockout of Tyrosine Hydroxylase Impairs Cognitive Behaviors
por: Locke, Timothy M., et al.
Publicado: (2020)

Expression mediated by three partial sequences of the human tyrosine hydroxylase promoter in vivo
por: Rolland, Anne-Sophie, et al.
Publicado: (2016)

DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers
por: Jin, Mingyue, et al.
Publicado: (2022)

Genetic Variations of Tyrosine Hydroxylase in the Pathogenesis of Hypertension
por: Lee, Yu Ho, et al.
Publicado: (2016)

Neuromelanin in Parkinson’s Disease: Tyrosine Hydroxylase and Tyrosinase
por: Nagatsu, Toshiharu, et al.
Publicado: (2022)

Distribution of Tyrosine Hydroxylase-Expressing Interneurons with Respect to Anatomical Organization of the Neostriatum
por: Ünal, Bengi, et al.
Publicado: (2011)

Quantitative Diffusion-Weighted MRI of Neuroblastoma
por: Abele, Niklas, et al.
Publicado: (2023)

Differential Expression of Tyrosine Hydroxylase Protein and Apoptosis-Related Genes in Differentiated and Undifferentiated SH-SY5Y Neuroblastoma Cells Treated with MPP(+)
por: Khwanraj, Kawinthra, et al.
Publicado: (2015)

A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions
por: Zwicker, Paula, et al.
Publicado: (2023)

Putaminal Mosaic Visualized by Tyrosine Hydroxylase Immunohistochemistry in the Human Neostriatum
por: Morigaki, Ryoma, et al.
Publicado: (2016)

ASL Metabolically Regulates Tyrosine Hydroxylase in the Nucleus Locus Coeruleus
por: Lerner, Shaul, et al.
Publicado: (2019)

Relevance of Electrostatics for the Interaction of Tyrosine Hydroxylase with Porous Silicon Nanoparticles
por: Bezem, Maria T., et al.
Publicado: (2021)

Cardiac tyrosine hydroxylase activation and MB-COMT in dyskinetic monkeys
por: Cuenca-Bermejo, Lorena, et al.
Publicado: (2021)

TNFα increases tyrosine hydroxylase expression in human monocytes
por: Gopinath, Adithya, et al.
Publicado: (2021)

Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency
por: Champagne, Marjolaine, et al.
Publicado: (2022)

The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis
por: Zhou, Zhi Dong, et al.
Publicado: (2022)

HGG-13. Combined CDK inhibition and arginine-deprivation as targeted therapy for arginine-auxotrophic glioblastoma multiforme cells
por: Riess, Christin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vpe3d2j04j09q4r041ic7p81hv